This is the second in a three-part blog series on National Pharmacovigilance systems and the role of technology in bridging the gaps in pharmacovigilance of regulatory authorities around the world.
As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants
This is the second in a three-part blog series on National Pharmacovigilance systems and the role of technology in bridging the gaps in pharmacovigilance of regulatory authorities around the world.
As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants
2017年11月28日、ArisGlobalはDIAとのウェビナー「How Automation Can Deliver the Holy Grail in Safety」を開催した：生産性、コンプライアンス、品質の達成」を開催しました。 このウェビナーで、私たちは聴衆にいくつかの質問を投げかけ、興味深い情報を得ました。 私たちはこれを受け、PVエコシステムにおける私たちの顧客にとってこれが何を意味するのか、少し考えてみました。
Automation technologies are having a major impact on performance and productivity across industries. In regulatory, these technologies also have the potential to reshape many activities across regulatory, leading to significant productivity gains. While there’s a lot of talk about how automation technologies will create new roles with exciting opportunities, the most powerful impact will be on the data quality and the efficiency with which manual tasks will be accomplished.
2017年11月28日、ArisGlobalはDIAとのウェビナー「How Automation Can Deliver the Holy Grail in Safety」を開催した：生産性、コンプライアンス、品質の達成」を開催しました。 このウェビナーで、私たちは聴衆にいくつかの質問を投げかけ、興味深い情報を得ました。 私たちはこれを受け、PVエコシステムにおける私たちの顧客にとってこれが何を意味するのか、少し考えてみました。
The presentation explores productivity gains from automation in other settings ...
THE CLIENT NEED A full-service contract research organization headquartered in ...
Life sciences companies confront increasingly stringent requirements on safety signal detection and risk management. Regulatory authorities are taking steps to further safeguard patients by requiring companies to take more comprehensive steps to assess and monitor the benefit-risk balance of their products.
